BLACKYAK hosts Namche Summit to advance Himalayan climate action and global solidarity
By PR Newswire
June 08, 2026 | 11:12
BLACKYAK has hosted the Himalayan Climate Charter 2026 Namche Summit to highlight the climate crisis facing the Himalayas and underscore the need for international solidarity and collective climate action.
Sapu Bioscience expands Sapu003 Phase 1b program with Global Clinical Trials as lead CRO
By PR Newswire
June 08, 2026 | 11:09
Sapu Bioscience has announced the expansion of its Phase 1b clinical development program for Sapu003 and the appointment of Global Clinical Trials as lead contract research organization for the international program.
Fox ESS launches refreshed brand identity and full energy portfolio at SNEC 2026
By PR Newswire
June 08, 2026 | 11:05
Fox ESS has concluded SNEC 2026 after officially launching its refreshed brand identity and showcasing a full-scale renewable energy product portfolio including residential and commercial solutions.
Delayed childbearing and infertility drive rising demand for cross-border fertility care
By PR Newswire
June 08, 2026 | 10:52
A new report highlights how regulation, cost, and access are shaping international family choices, with Asian case studies illustrating the growing demand for cross-border fertility care driven by delayed childbearing and rising infertility rates.
Finnate listed on MAS Pathfinder Programme after independent review and verification
By PR Newswire
June 08, 2026 | 10:49
Finnate has been listed on the PathFin.ai Knowledge Hub under Singapore's MAS Pathfinder Programme following an independent review and verification process reflecting its governance-focused design and deployment maturity in regulated financial services.
Antengene presents first ATG-207 preclinical data on immune tolerance at EULAR 2026
By PR Newswire
June 08, 2026 | 10:39
Antengene has presented first preclinical data at EULAR 2026 showing its ATG-207 compound promotes regulatory T cell induction and immune tolerance, advancing its pipeline for autoimmune diseases.
Indonesian firms face 18.9% delivery cost surge as APAC supply chains pivot to AI
By PR Newswire
June 08, 2026 | 10:34
Indonesian retail and logistics sectors are aggressively restructuring supply chains following a report revealing an 18.9% surge in delivery costs and a strong consumer preference for predictability over speed across Asia-Pacific.
Thailand logistics sectors face 18.9% delivery cost surge as supply chains pivot to AI
By PR Newswire
June 08, 2026 | 10:31
Thailand's retail and logistics sectors are urgently restructuring supply chains following a report revealing an 18.9% surge in delivery costs and a two-to-one consumer preference for predictability over speed.
Everest Medicines acquires rights to develop and commercialize LNZ100 in Greater China
By PR Newswire
June 08, 2026 | 10:27
Everest Medicines has entered into an asset purchase agreement with Corxel Pharmaceuticals to develop and commercialize LNZ100, an innovative therapeutic, across Greater China.
Ascletis presents obesity portfolio data including ASC30 clinical results at ADA 2026
By PR Newswire
June 08, 2026 | 10:13
Ascletis Pharma has presented three key studies at the ADA 2026 Scientific Sessions in New Orleans, highlighting its differentiated obesity portfolio including ASC30 clinical data and preclinical findings from ASC37 and ASC39.
Ractigen saRNA therapy converts white fat to brown fat for weight loss at ADA 2026
By PR Newswire
June 08, 2026 | 10:07
Ractigen Therapeutics has presented late-breaking preclinical data at ADA 2026 showing its LiCO-saUcp1 saRNA therapy converts white fat into calorie-burning brown fat, driving significant fat loss while preserving lean muscle mass and preventing weight rebound.
Guild Wars 3 announced at Summer Game Fest for PC and PlayStation 5
By PR Newswire
June 08, 2026 | 10:04
Guild Wars 3 has been announced at Summer Game Fest for PC and PlayStation 5, marking the first time a game in the legendary franchise will come to consoles.
OriCell's GPC3 CAR-T therapy Ori-C101 receives NMPA clearance for Phase II liver cancer trial
By PR Newswire
June 08, 2026 | 10:00
OriCell Therapeutics has announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration to proceed to a confirmatory Phase II trial in late-line advanced hepatocellular carcinoma.
Latest News
Mobile Version